Citi raised the firm’s price target on BeiGene to $288 from $269 and keeps a Buy rating on the shares post the Q2 report. The analyst says Brukinsa is quickly emerging as the preferred BTKi in the U.S. chronic lymphocytic leukemia market since approval only six quarters ago, capturing 70% of the growth in the covalent BTKi class in Q2.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: